Neurocrine Biosciences, Inc. (NBIX) Posts Q3 EPS of $0.56, Revenues Rose 189% Y/Y
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts NBIX Hot Sheet
Price: $145.35 -0.51%
Financial Fact:
Deferred gain on real estate: 853K
Today's EPS Names:
LTBR, AES, SYRS, More
Financial Fact:
Deferred gain on real estate: 853K
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) reported Q3 EPS of $0.56, which may not compare to the analyst estimate of $0.19. Revenue for the quarter came in at $41.6 million versus the consensus estimate of $21.64 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Neurocrine Biosciences (NBIX) Tops Q3 EPS by 138c
- Ryman Hospitality Properties (RHP) Tops Q3 EPS by 15c
- ONE Gas (OGS) Tops Q3 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
